The application of hydroxypropyl betacyclodextrin in ivermox tablets

Ivermox is an inhibitor of mTOR (a mammalian target of rapamycin), a serine threonine kinase downstream of the PI3K/AKT pathway.Ivermox was developed by Novartis of Switzerland with the trade name Certican. It was listed in Sweden for the first time in 2003.It is fda-approved for use in patients who have failed to treat advanced kidney cancer with either sunitinib or sorafenib, and according to the novartis study, ivermox can slow the growth of kidney cancer cells and reduce mortality by 67 percent.Ivermox, hydroxypropyl betacyclodextrin and deoxycholic acid were dissolved in anhydrous ethanol, then the solution was granulated on medically acceptable excipients, dried and mixed with lubricant and pressed into tablets.Compared with the existing technology, the invention has the advantages of simple preparation process, uniform drug dispersion, smooth production process and rapid drug dissolution.